Loading...
•
Jun 30
Orthofix Q2 2025 Earnings Report
Orthofix reported its financial results for the second quarter ended June 30, 2025, demonstrating progress on its three-year business transformation plan.
Key Takeaways
Orthofix reported net sales of $203.1 million for the second quarter of 2025, a 2.3% increase year-over-year. The company achieved a net loss of $(14.1) million, or $(0.36) per share, and reported positive free cash flow of $4.5 million. Pro forma adjusted EBITDA increased by 24.1% to $20.6 million, with margin expansion for the sixth consecutive quarter.
Second quarter 2025 net sales reached $203.1 million, showing a 2.3% increase compared to the second quarter of 2024.
The company reported a net loss of $(14.1) million, or $(0.36) per share, for the quarter.
Non-GAAP pro forma adjusted EBITDA was $20.6 million, representing a 24.1% growth and approximately 190 basis points of margin expansion year-over-year.
Orthofix generated positive free cash flow of $4.5 million during the second quarter of 2025.
Orthofix
Orthofix
Orthofix Revenue by Segment
Revenue by Segment
Bone Growth Therapies Revenue
CapyFin.comSpinal Implants, Biologics and Enabling Technologies Revenue
CapyFin.comGlobal Spine Revenue
CapyFin.comGlobal Orthopedics Revenue
CapyFin.com Forward Guidance
Orthofix reaffirmed its full-year 2025 net sales, adjusted EBITDA, and free cash flow guidance.
Positive Outlook
- Pro forma net sales are expected to range between $808 million to $816 million, excluding discontinued M6® product lines.
- Pro forma non-GAAP adjusted EBITDA is expected to be $82 million to $86 million.
- Free cash flow is expected to be positive for full-year 2025, excluding restructuring charges related to M6® product lines.
- Guidance is based on current foreign currency exchange rates.
- The company expects to benefit from recent product launches and deliver meaningful product innovation.
Challenges Ahead
- Guidance does not account for additional potential exchange rate changes that may occur this year.
- The company is unable to provide expectations of GAAP net income (loss) on a forward-looking basis due to unpredictable excluded items.
- Restructuring charges related to the discontinuation of M6® product lines will impact free cash flow.
- The M6® product lines have been discontinued, impacting future sales.
- Uncertainties remain regarding the ultimate outcome of various factors that determine GAAP results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income